Mizuho Lifts Harmony Biosciences Target to $50, Citing Confidence in Fragile X Trial
Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) is one of the best cheap growth stocks to buy according to analysts.
Harmony Biosciences Holdings Inc. (HRMY)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Marshall Wace LLP Paul Marshall And Ian Wace | 1,209,484 | $38,219,694 | +37% | 0.04% |
| 2. | Renaissance Technologies Jim Simons | 929,471 | $29,371,284 | +11% | 0.04% |
| 3. | Arrowstreet Capital Peter Rathjens, Bruce Clarke And John Campbell | 906,909 | $28,658,324 | +128% | 0.02% |
| 4. | 683 Capital Partners Ari Zweiman | 302,000 | $9,543,200 | +1% | 0.63% |
| 5. | Tang Capital Management Kevin C. Tang | 281,200 | $8,885,920 | 0.45% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $24.00 | 339,476 | $8,147,424.00 | 10,651,120 | 2020-08-21 | Filing | |
| $34.30 | 3,922 | $134,524.60 | 42,702 | 2020-08-26 | Filing | |
| $34.20 | 823 | $28,146.60 | 38,780 | 2020-08-25 | Filing | |
| $24.00 | 132,503 | $3,180,072.00 | 4,409,803 | 2020-08-21 | Filing | |
| $34.30 | 3,057 | $104,855.10 | 37,957 | 2020-08-24 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $33.12 | 740 | $24,505.25 | 0 | 2025-04-01 | Filing | |
| $32.48 | 6,247 | $202,880.70 | 740 | 2025-04-01 | Filing | |
| $33.23 | 500 | $16,615.10 | 0 | 2025-03-03 | Filing | |
| $32.61 | 4,369 | $142,474.40 | 500 | 2025-03-03 | Filing | |
| $38.02 | 1,629 | $61,941.10 | 0 | 2025-01-27 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 6,736,939 | $212,887,273 | 0% | |
| 2. | 6,618,033 | $209,129,843 | 87.82% | |
| 3. | 5,110,780 | $161,500,648 | 0% | |
| 4. | 4,688,192 | $148,146,870 | 0.01% | |
| 5. | 1,629,246 | $51,484,174 | 0% |
News See All
H.C. Wainwright Remains a Buy on Harmony Biosciences Holdings (HRMY)
Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) is one of the top most undervalued biotech stocks to buy now. H.C.
10 Best Cheap Growth Stocks to Buy According to Analysts
The summer of 2025 has produced a split-screen market.
10 Most Undervalued Biotech Stocks to Buy Now
On July 25, Salveen Richter, Goldman Sachs' lead biotech analyst, appeared on CNBC’s ‘Squawk Box’ to talk about the state of the biotech sector and what to expect from the earnings season, among...
Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) Q2 2025 Earnings Call Transcript
Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) Q2 2025 Earnings Call Transcript August 5, 2025Harmony Biosciences Holdings, Inc. misses on earnings expectations.
Harmony Biosciences Holdings, Inc. (HRMY): A Bull Case Theory
We came across a bullish thesis on Harmony Biosciences Holdings, Inc. on In. Specter’s Substack. In this article, we will summarize the bulls’ thesis on HRMY.
Harmony Biosciences Advances Pipeline While Navigating Analyst Caution
Headquartered in New Jersey, Harmony Biosciences Holdings, Inc.
13 Best Low Risk High Growth Stocks to Buy
The current market is witnessing political chess moves, which are also affecting policy changes.
Mizuho Reaffirms “Outperform” on Harmony Biosciences (HRMY) for BP1.15205 Data
Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) is one of the 7 most undervalued pot stocks to buy according to analysts.
7 Most Undervalued Pot Stocks To Buy According To Analysts
The global cannabis market was worth $26.86 billion in 2022, Spherical Insights & Consulting data shows. Three years later, Mordor Intelligence valued the market at $44.60 billion.